Company / Depreciation & Amortization
Sunshine Biopharma Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$223.5K
FY2025
5-year range
$12.7K / $223.5K
FY2021-FY2025
Trend
+49.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has increased for 3 consecutive years, from $12,741 in FY2022 to $223,527 in FY2025.
Based on SEC 10-K filings.
$223,527 in FY2025 with a 5-year CAGR of +74.6%.
Increased from $25,163 to $223,527 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +159.8%
- 5-Year CAGR
- +74.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- Sunshine Biopharma Inc.'s depreciation & amortization has grown for 3 consecutive years.
- 5-year CAGR of +74.6%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 49.9% year-over-year.
- Lowest depreciation & amortization in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $223.5K | +49.9% |
| FY2024 | $149.1K | +492.7% |
| FY2023 | $25.2K | +97.5% |
| FY2022 | $12.7K | -9.4% |
| FY2021 | $14.1K | +2.1% |
| FY2020 | $13.8K | -72.1% |
| FY2019 | $49.4K | +644.6% |
| FY2018 | $6.6K | -89.1% |
| FY2017 | $60.7K | +1328.6% |
| FY2016 | $4.3K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026